Citigroup
XBIO icon

Citigroup’s Xenetic Biosciences XBIO Stock Holding History

Citigroup’s Portfolio XBIO Stock Details XBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,241
Closed -$2.69K – 6451
2025
Q4 		$2.69K Buy
+1,241
New +$3.96K ﹤0.01% 5403

Other funds holding XBIO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
DWM
Darwin Wealth Management Tampa, Florida $365M AUM 22.69% 1-Year Est. Return

Citigroup's XBIO Position: Q1 2026 in Review

Citigroup sold out of Xenetic Biosciences (XBIO) in Q1 2026, closing a stake of 1,241 shares — an estimated $2.69K sold.

Citigroup first reported a position in XBIO in Q4 2025 and held it in 1 quarter. The position peaked at $2.69K in Q4 2025. 6 funds tracked by Wall St. Rank hold XBIO as of Q1 2026.

  • Citigroup reported no remaining Xenetic Biosciences position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 1,241 Xenetic Biosciences shares in Q1 2026, an estimated $2.69K.
  • Citigroup first reported a position in Xenetic Biosciences in Q4 2025 and held it in 1 quarter.
  • Citigroup's Xenetic Biosciences position peaked at $2.69K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.